Lung Cancer Plasma
Lung Cancer Plasma - Cryopreserved human plasma from clinically confirmed lung cancer donors. Ideal for circulating tumour DNA (ctDNA), extracellular vesicle, and protein biomarker research, plus soluble checkpoint and cytokine profiling. Stratified by histology, stage, driver mutation, and treatment line.
| Lot # | Condition | Volume | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 77841 | Lung Cancer | 1.0 ML | Hispanic/Latino | 67 | Female | 25 | $667.00 | |||
| 75963 | Lung Cancer | 1.0 ML | Hispanic/Latino | 62 | Female | 18 | $667.00 | |||
| 75959 | Lung Cancer | 1.0 ML | Hispanic/Latino | 70 | Female | 20 | $667.00 | |||
| 76765 | Lung Cancer | 1.0 ML | 67 | Male | Ukraine |
No medications
|
1 | $667.00 | ||
| 76760 | Lung Cancer | 1.0 ML | 62 | Male | Ukraine |
Cardiomagnyl
|
1 | $667.00 | ||
| 76761 | Lung Cancer | 1.0 ML | 62 | Male | Ukraine |
Cardiomagnyl
|
1 | $667.00 | ||
| 76768 | Lung Cancer | 1.0 ML | 73 | Male | Ukraine |
Cardiomagnyl
|
1 | $667.00 | ||
| 76767 | Lung Cancer | 1.0 ML | 73 | Male | Ukraine |
Cardiomagnyl
|
1 | $667.00 | ||
| 76766 | Lung Cancer | 1.0 ML | 62 | Male | Ukraine |
No medications
|
1 | $667.00 | ||
| 76742 | Lung Cancer | 1.0 ML | Female | Ukraine |
No medications
|
1 | $667.00 |
Lung Cancer Plasma for Liquid Biopsy and Tumour Immunology Research
Lung Cancer Plasma is collected from IRB-consented donors clinically diagnosed with lung cancer and processed within one day of collection to preserve circulating tumour DNA, extracellular vesicles, cytokines, proteins, and metabolites. Lung cancer is a neoplastic disease driven by somatic driver mutations and copy-number changes, with tumour-immune interactions in the microenvironment shaping progression and treatment response. Plasma is acellular and is the standard matrix for liquid biopsy and soluble-analyte work.
Tumour Biology and Why Plasma
- Circulating tumour DNA (ctDNA) released by apoptotic and necrotic tumour cells enables non-invasive detection of driver alterations, including EGFR, KRAS, ALK, ROS1, BRAF, and MET, as well as resistance mutations that emerge on targeted therapy.
- Plasma is the correct matrix for cell-free DNA: serum yields substantially more background genomic DNA from leukocyte lysis during clotting, diluting the tumour fraction.
- Tumour-derived extracellular vesicles and exosomes carry protein, RNA, and lipid cargo used for early-detection and monitoring research.
- Protein biomarkers including CEA, CYFRA 21-1, and neuron-specific enolase (NSE, particularly in small cell lung cancer) support marker validation studies.
- Tumour immunology: soluble PD-L1, soluble immune checkpoint molecules, and cytokine and chemokine profiles are used to study immune evasion and immune checkpoint inhibitor response.
- Cancer-associated inflammation and cachexia markers, including IL-6 and acute-phase proteins, are measurable in the same aliquot.
Donor Stratification Available
- Histology: non-small cell lung cancer (adenocarcinoma, squamous cell carcinoma) versus small cell lung cancer
- Stage at collection, including early-stage versus metastatic disease
- Driver mutation status where available (EGFR, KRAS, ALK, ROS1, BRAF)
- PD-L1 expression status where available
- Treatment status and line of therapy: treatment-naive, on targeted therapy, on immune checkpoint inhibitor, on chemotherapy, or post-progression
- Smoking history: current, former, or never-smoker
- Longitudinal or serial collections from the same donor, on request
- Matched healthy controls available
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed lung cancer donors
- Processed within one day of collection
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request
- Anticoagulant selection available on request to match your assay, including cell-free DNA workflows
De-identified Donor Data
- Verified lung cancer diagnosis, with histology and stage where available
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Smoking history and treatment history where available
- Additional lung cancer-specific metadata available
Applications
- ctDNA extraction, targeted sequencing, and mutation detection assay development
- Cell-free DNA methylation and fragmentomics research
- Minimal residual disease and treatment-monitoring biomarker studies
- Extracellular vesicle and exosome isolation and cargo profiling
- Protein tumour marker validation (CEA, CYFRA 21-1, NSE)
- Soluble checkpoint molecule and cytokine profiling for immunotherapy response research
- Plasma proteomics and metabolomics for early detection
- Diagnostic platform validation and liquid biopsy panel development
Other Lung Cancer Specimen Types
Lung cancer donor material is also available as Lung Cancer Serum, Lung Cancer PBMC, Lung Cancer Whole Blood, and Lung Cancer Leukopak. Histology-specific products include Non Small Cell Lung Cancer Plasma and Lung Adenocarcinoma Whole Blood.
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Lung cancer plasma is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. For the full specimen range, see our human plasma collection.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.